{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["glofitamab","obinutuzumab"]],"indication":"relapsed/refractory diffuse large B-cell lymphoma after CAR-T therapy","name":"BiCAR","nct_id":"NCT04703686","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bicar-nct04703686. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Obinutuzumab + RO7082859","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-05-21","type":"ACTUAL"},"conditions":["Diffuse Large B-Cell Lymphoma Refractory","Refractory Indolent Adult Non-Hodgkin Lymphoma","Refractory Transformed B-cell Non-Hodgkin Lymphoma","Refractory Primary Mediastinal Large B-Cell Cell Lymphoma","Refractory Mantle Cell Lymphoma"],"enrollment":{"count":67,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Obinutuzumab","otherNames":["gazyva"],"type":"DRUG"},{"name":"RO7082859","otherNames":["glofitamab"],"type":"DRUG"}],"last_update":"2026-03-16","lead_sponsor":"The Lymphoma Academic Research Organisation","official_title":"A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-01-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"4 years"}],"references":[{"citation":"Cartron G, Chaillol I, Houot R, Al Tabaa Y, Le Bras F, Ysebaert L, Choquet S, Jardin F, Bay JO, Gros FX, Morschhauser F, Rossi C, Gastinne T, Thieblemont C, Joris M, Ricard L, Regny C, La Rochelle LD, Feugier P, Marcais A, Ould-Ammar R, Tarte K, Laurent C, Sesques P. Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm. J Hematol Oncol. 2026 Jul 1. doi: 10.1186/s13045-026-01816-4. Online ahead of print.","pmid":"42393723","type":"DERIVED"}],"start_date":{"date":"2021-03-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy","url":"https://clinicaltrials.gov/study/NCT04703686"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bicar-nct04703686"}